Therefore, our results suggest that an increased level of AKR1B10 in the lung of COVID-19 patients may participate in the production of cytokines associated with the ARDS, an observation which could open promising perspectives to reinforce the therapeutic arsenal for the COVID-19 disease. Here, AKR1B10 is linked to acute respiratory distress syndrome.